Algert Global LLC Acquires 94,653 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Algert Global LLC increased its position in Kiniksa Pharmaceuticals by 69.7%, owning 230,467 shares valued at approximately $5.12 million as of the end of the first quarter.
• Kiniksa Pharmaceuticals' CEO Sanj K. Patel sold 62,116 shares at an average price of $27.33, reducing his ownership by 39.12%.
• The company's earnings results showed an EPS of $0.23, surpassing estimates, with analysts maintaining a "buy" rating and a consensus target price of $41.17.

Algert Global LLC boosted its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 69.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 230,467 shares of the company's stock after acquiring an additional 94,653 shares during the quarter. Algert Global LLC owned 0.32% of Kiniksa Pharmaceuticals International worth $5,119,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its stake in Kiniksa Pharmaceuticals International by 4.0% in the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock valued at $326,000 after acquiring an additional 568 shares during the last quarter. MetLife Investment Management LLC increased its stake in Kiniksa Pharmaceuticals International by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after acquiring an additional 1,374 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Kiniksa Pharmaceuticals International by 6.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock valued at $432,000 after acquiring an additional 1,380 shares during the last quarter. Finally, US Bancorp DE bought a new position in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $33,000. 53.95% of the stock is owned by institutional investors.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company's stock, valued at approximately $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, August 18th. The shares were sold at an average price of $33.77, for a total transaction of $547,074.00. Following the completion of the sale, the chief operating officer directly owned 40,215 shares of the company's stock, valued at approximately $1,358,060.55. This trade represents a 28.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 674,849 shares of company stock valued at $21,144,188. 53.48% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Trading Up 0.5%

KNSA stock traded up $0.17 during midday trading on Friday, hitting $33.75. The stock had a trading volume of 356,168 shares, compared to its average volume of 691,871. The firm has a market cap of $2.50 billion, a P/E ratio of 843.96 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $34.55. The business has a fifty day moving average price of $29.78 and a two-hundred day moving average price of $25.57.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on KNSA shares. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.